Basilea Pharmaceutica AG BPMUF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 58.42M | 58.89M | 65.00M | 64.91M | 54.86M |
| Total Other Revenue | 16.88M | 17.02M | 15.38M | 15.36M | 8.16M |
| Total Revenue | 75.31M | 75.91M | 80.37M | 80.27M | 63.01M |
| Cost of Revenue | 43.95M | 44.30M | 51.75M | 51.69M | 37.90M |
| Gross Profit | 31.35M | 31.60M | 28.62M | 28.58M | 25.12M |
| SG&A Expenses | 11.10M | 11.19M | 11.18M | 11.16M | 10.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.05M | 55.49M | 62.93M | 62.85M | 48.23M |
| Operating Income | 20.26M | 20.42M | 17.44M | 17.42M | 14.78M |
| Income Before Tax | 20.34M | 20.51M | 16.60M | 16.58M | 11.73M |
| Income Tax Expenses | 2.66M | 2.68M | 1.31M | 1.31M | 2.15M |
| Earnings from Continuing Operations | 17.69M | 17.83M | 15.29M | 15.27M | 9.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.69M | 17.83M | 15.29M | 15.27M | 9.58M |
| EBIT | 20.26M | 20.42M | 17.44M | 17.42M | 14.78M |
| EBITDA | 20.32M | 20.48M | 18.66M | 18.63M | 15.30M |
| EPS Basic | 1.43 | 1.44 | 1.25 | 1.25 | 0.78 |
| Normalized Basic EPS | 1.03 | 1.04 | 0.85 | 0.85 | 0.62 |
| EPS Diluted | 1.34 | 1.35 | 1.18 | 1.18 | 0.78 |
| Normalized Diluted EPS | 0.93 | 0.93 | 0.77 | 0.77 | 0.60 |
| Average Basic Shares Outstanding | 12.37M | 12.37M | 12.24M | 12.24M | 12.25M |
| Average Diluted Shares Outstanding | 13.81M | 13.81M | 13.52M | 13.52M | 12.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |